Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2024-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and committee meetings, supervision activities, and evaluation of company governance and financial matters during the year 2023. The content focuses on the independent director's duties, oversight of financial reporting, audit committee activities, and corporate governance. It is a detailed report on the independent director's role and activities rather than a general annual report or financial statement. This type of document is best classified under Board/Management Information (MANG) as it relates to management and board-level disclosures about director activities and governance oversight.
2024-04-25 Chinese
2023年度独立董事述职报告-肖兴刚
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and committee meetings, communication with auditors, oversight activities, and evaluation of company governance and shareholder interests for the year 2023. The content focuses on the independent director's duties, activities, and opinions rather than financial results or audit opinions alone. It is a report by a board member about their management and governance role, not a full annual report, audit report, or earnings release. This fits the category of Board/Management Information (MANG), which covers announcements about board or senior management activities and reports. The document length is over 5,000 characters and contains substantive content about management oversight and governance. Therefore, the classification is MANG with high confidence.
2024-04-25 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告全文" which translates to "2023 Annual Report Full Text" for 西藏易明西雅医药科技股份有限公司. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes signed financial statements and an audit report, confirming it is the official comprehensive yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled '股东大会议事规则' which translates to 'Rules of Procedure for the Shareholders' General Meeting' of 西藏易明西雅医药科技股份有限公司. It details the procedures, rules, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, the process for convening meetings, voting procedures, and other governance-related matters. There is no financial data, earnings information, or report content. Instead, it is a governance document outlining internal rules and practices related to shareholder meetings. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, supporting a high confidence in classification.
2024-04-25 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of the company 西藏易明西雅医药科技股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, and instructions for shareholders. The document does not contain financial statements or detailed financial performance data but rather serves as an official notification and procedural guide for the AGM. It also includes an authorization proxy form for shareholders to delegate voting rights. Given the content and purpose, this document fits the category of AGM Information (AGM-R).
2024-04-25 Chinese
审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee regarding the performance and supervision of the accounting firm (立信会计师事务所) for the 2023 fiscal year audit. It details the audit firm's qualifications, the audit process, communication with management, and an overall evaluation of the audit work done for the 2023 annual financial statements. The document does not contain the full annual report or financial statements but is a standalone report on the audit firm's supervision and performance. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related evaluations. The document length is 2259 characters, which is consistent with a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2023
2024-04-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.